Trial reportBlood advances2020
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
Trial report in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02400437 (Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations.Bone marrow transplantation · 2025Guideline
- Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom macroglobulinemia.Blood advances · 2026Article
- The Direction of Modern Therapies in Waldenström Macroglobulinaemia.Journal of cellular and molecular medicine · 2025Review
- Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis.Blood cancer journal · 2025Article
- Article
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy.Mediterranean journal of hematology and infectious diseases · 2025Review
- Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia.Hematological oncology · 2024Review
- Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy.Journal of Zhejiang University. Science. B · 2024Article
- Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia.Current hematologic malignancy reports · 2024Review
- Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.Current hematologic malignancy reports · 2024Review
- Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.Annals of hematology · 2024Review
- Advances in Treatment of Waldenström Macroglobulinemia.Current oncology reports · 2023Review
- Current approach to Waldenström macroglobulinemia.Blood reviews · 2023Review
- Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.American journal of hematology · 2023Article
- A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.Current oncology (Toronto, Ont.) · 2022Article
- A Focus on Waldenström Macroglobulinemia and AL Amyloidosis.Journal of the advanced practitioner in oncology · 2022Article
- Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.Haematologica · 2022Article
- Monoclonal antibody-based therapies for Waldenström's macroglobulinemia.Leukemia research reports · 2022Article
- NF-κB signaling in inflammation and cancer.MedComm · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteasome inhibition is a standard of care for the primary treatment of patients with Waldenström macroglobulinemia (WM). We present the long-term follow-up of a prospective, phase II clinical trial that evaluated the combination of ixazomib, dexamethasone, and rituximab (IDR) in 26 treatment-naive patients with WM. IDR was administered as 6 monthly induction cycles followed by 6 every-2-month maintenance cycles. The MYD88 L265P mutation was detected in all patients, and CXCR4 mutations were detected in 15 patients (58%). The median time to response (TTR) and time to major response (TTMR) were 2 and 6 months, respectively. Patients with and without CXCR4 mutations had median TTR of 3 months and 1 month, respectively (P = .003), and median TTMR of 10 months and 3 months, respectively (P = .31). The overall, major, and very good partial response (VGPR) rates were 96%, 77%, and 19%, respectively. The rate of VGPR in patients with and without CXCR4 mutations were 7% and 36%, respectively (P = .06). The median progression-free survival (PFS) was 40 months, the median duration of response (DOR) was 38 months, and the median time to next treatment (TTNT) was 40 months. PFS, DOR, and TTNT were not affected by CXCR4 mutational status. The safety profile was excellent with no grade 4 adverse events or deaths to date. IDR provides a safe and effective frontline treatment option for symptomatic patients with WM. This study was registered at www.clinicaltrials.gov as #NCT02400437.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.